Reynders McVeigh Capital Management’s Pacific Biosciences PACB Stock Holding History

Reynders McVeigh Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-113,480	Closed	-$1.03M	–	229
2022 Q1	$1.03M	Sell	113,480 -31,970	-22%	-$368K	0.06%	103
2021 Q4	$2.98M	Buy	145,450 +14,720	+11%	+$355K	0.17%	63
2021 Q3	$3.34M	Buy	130,730 +11,765	+10%	+$349K	0.2%	64
2021 Q2	$4.16M	Buy	118,965 +14,780	+14%	+$430K	0.25%	56
2021 Q1	$3.47M	Buy	104,185 +36,055	+53%	+$1.26M	0.23%	62
2020 Q4	$1.77M	Buy	+68,130	New	+$1.16M	0.12%	79

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Reynders McVeigh Capital Management's PACB Position: Q2 2022 in Review

Reynders McVeigh Capital Management sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 113,480 shares — an estimated $1.03M sold.

Reynders McVeigh Capital Management first reported a position in PACB in Q4 2020 and held it in 6 quarters. The position peaked at $4.16M in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

Reynders McVeigh Capital Management reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
Reynders McVeigh Capital Management sold 113,480 Pacific Biosciences shares in Q2 2022, an estimated $1.03M.
Reynders McVeigh Capital Management first reported a position in Pacific Biosciences in Q4 2020 and held it in 6 quarters.
Reynders McVeigh Capital Management's Pacific Biosciences position peaked at $4.16M in Q2 2021.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Reynders McVeigh Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.